← The Procter & Gamble Company

PG · Forward model · Jejurikar case

The Jejurikar case, 20 quarters out

Model as of

Each segment is projected from its own operating driver, rolled up into consolidated cash flow, and discounted back to a fair value per share. The assumptions below are editable — change them and every number on this page moves with them.

Every revenue line here is a reportable segment P&G discloses, not an apportionment. The five operating segments plus Corporate sum to reported consolidated net sales in all twenty quarters, with a largest residual of $2m on $21bn - P&G's own rounding in its $-million segment table. Sixteen of the twenty quarters per line are read from a filed segment table; the four April-June quarters are derived as fiscal-year segment total less the disclosed nine-month segment column and are marked estimated, and the most recent of them is independently confirmed line by line in the Q4 fiscal 2026 8-K. NOT disclosed and therefore not modelled: any dollar split of a segment into its named categories - P&G publishes only whole-percent-of-company shares such as 'Fabric Care 23%' - any geographic split below US and international totals, any unit, volume or household count, and any allocation of restructuring cost to a segment. Because P&G discloses no operational level for any segment, every vertical uses the growth driver; the volume, currency, price, mix and acquisition percentages the company does publish are evidence for the rate, not a level to model. Segment EBITDA margins are fiscal 2026 GAAP figures - (segment earnings before income taxes + segment depreciation and amortisation) / segment net sales - because segment D&A is disclosed annually only; the June quarter itself was restructuring-depressed at 18.6% GAAP operating margin against 19.5% core. The whole of the restructuring programme, the interest line and the unallocated overhead sit in the Corporate vertical, so corporate.overheadPctRevenue is zero to avoid counting them twice. The 20% tax rate is P&G's guided fiscal 2027 core effective rate. Consensus EPS for this company is a core figure and must never be paired with the site's stored GAAP EPS: the June quarter's $1.43 core beat a $1.41-$1.42 street number, while GAAP was $1.26.

PG forward model
Horizon
Fair value per share $136.65 −4% against $142.97
Terminal-year revenue $95.00B last four projected quarters
Enterprise value $341.82B $67.64B explicit + $274.19B terminal

The new CEO's own framing, taken literally. Shailesh Jejurikar took over in January 2026 and told the July call that P&G would accelerate growth from semester to semester, with the cost headwind anniversaried by the back half. This case leaves the first half of fiscal 2027 exactly on the trailing run-rate while the $1bn after-tax cost vintage sits in it, then steps the five operating segments up 2.56% in level from the January-March 2027 quarter onward - Corporate is left alone, because an overhead residual should not be stepped up with the operating lines. The second half then prints $43.71bn, 3.0% above the same half of fiscal 2026, which is the top of the guided range; the year lands at $88.52bn, +1.70%. What this case does NOT reach is the guidance midpoint of about $88.77bn: a first half held at the trailing rate is too big a hole for one good half to fill, and getting there would need the second half to run above the top of the guided range. Fair value is $136.65, still 5.8% below the price, because a shaped year at 15x is worth about $3.60 a share more than a flat one, not $12.

PG REVENUE MODEL

Latest: $23.36B (2031Q2E)

Period Value
2021Q3 $20.34B
2021Q4 $20.95B
2022Q1 $19.38B
2022Q2 $19.52B
2022Q3 $20.61B
2022Q4 $20.77B
2023Q1 $20.07B
2023Q2 $20.55B
2023Q3 $21.87B
2023Q4 $21.44B
2024Q1 $20.20B
2024Q2 $20.53B
2024Q3 $21.74B
2024Q4 $21.88B
2025Q1 $19.78B
2025Q2 $20.89B
2025Q3 $22.39B
2025Q4 $22.21B
2026Q1 $21.23B
2026Q2 $21.20B
2026Q3E $22.46B
2026Q4E $22.34B
2027Q1E $21.66B
2027Q2E $22.05B
2027Q3E $23.37B
2027Q4E $23.24B
2028Q1E $21.96B
2028Q2E $22.37B
2028Q3E $23.71B
2028Q4E $23.58B
2029Q1E $22.28B
2029Q2E $22.69B
2029Q3E $24.06B
2029Q4E $23.93B
2030Q1E $22.60B
2030Q2E $23.02B
2030Q3E $24.42B
2030Q4E $24.28B
2031Q1E $22.93B
2031Q2E $23.36B
Scenarios

Where each case comes from

Valuation

From cash flow to fair value

The published model, discounted at 7.0% a year with an exit multiple of 15.0x on EBITDA. The sliders above do not change this walk.

Present value of free cash flow, 20 quarters$67.64B
Terminal-year revenue$95.00B
Terminal-year EBITDA$25.64B
Exit multiple, on EBITDA15.0x
Terminal value$384.56B
Discounted at 7.0% a year, terminal value becomes$274.19B
Share of enterprise value from the terminal80%
Enterprise value$341.82B
Net cash−$24.20B
Equity value$317.63B
Shares2.32B
Fair value per share$136.65
Against the deployed price of $142.97, as of −4%

P&G trades at 15.77x trailing EBITDA: an enterprise value of $361.2bn - $337.0bn of market capitalisation on 2,324,433,060 shares at $145.00, plus $24.2bn of net debt - over fiscal 2026 EBITDA of $22,908m, which is reported operating income of $19,748m plus $3,160m of depreciation and amortisation. That is 21.9x trailing GAAP EPS of $6.62 and 20.7x the $7.00 core guidance midpoint; StockAnalysis independently shows 21.89x and 20.75x. The base case exits at 15.0x, a shade below today's rating, because a terminal multiple should not assume the current one survives five years on a company whose June-quarter organic sales growth was zero with volume, price and mix all flat. The 7.0% discount rate is a staples cost of capital for an A-rated issuer on a 3.0% dividend yield; P&G discloses no WACC. This one assumption dominates: $267.3bn of the base case's $333.4bn enterprise value, 80%, is the discounted exit multiple, and one turn of EBITDA on the $24.99bn terminal year is $17.8bn once discounted, about $7.66 a share.

Read the other way round: at $142.97 the market is paying 15.8x terminal-year EBITDA, holding every other assumption on this page fixed. That is the number to argue about.

Quarter by quarter

The projected path

Quarter BeautyGroomingHealth CareFabric & Home CareBaby, Feminine & Family CareCorporate Revenue YoY EBITDA Capex FCF R40 PV of FCF
2026 Q3E $4.38B$1.77B$3.18B$7.78B$5.05B$293M $22.46B 0% $5.91B $1.13B $3.83B +17 $3.76B
2026 Q4E $4.23B$1.78B$3.35B$7.63B$5.06B$293M $22.34B +1% $5.94B $1.13B $3.85B +18 $3.72B
2027 Q1E $3.98B$1.61B$3.10B$7.49B$5.19B$294M $21.66B +2% $5.79B $1.10B $3.75B +19 $3.56B
2027 Q2E $4.21B$1.76B$2.87B$7.71B$5.20B$295M $22.05B +4% $5.92B $1.12B $3.84B +21 $3.59B
2027 Q3E $4.64B$1.84B$3.32B$8.07B$5.20B$296M $23.37B +4% $6.29B $1.17B $4.09B +22 $3.76B
2027 Q4E $4.48B$1.85B$3.49B$7.91B$5.21B$296M $23.24B +4% $6.27B $1.17B $4.08B +22 $3.69B
2028 Q1E $4.11B$1.63B$3.14B$7.57B$5.21B$297M $21.96B +1% $5.92B $1.11B $3.85B +19 $3.42B
2028 Q2E $4.35B$1.79B$2.92B$7.80B$5.22B$298M $22.37B +1% $6.03B $1.13B $3.92B +19 $3.43B
2028 Q3E $4.79B$1.87B$3.37B$8.16B$5.22B$299M $23.71B +1% $6.40B $1.19B $4.17B +19 $3.58B
2028 Q4E $4.63B$1.87B$3.55B$8.00B$5.23B$299M $23.58B +1% $6.37B $1.18B $4.15B +19 $3.51B
2029 Q1E $4.25B$1.65B$3.19B$7.66B$5.23B$300M $22.28B +1% $6.02B $1.13B $3.91B +19 $3.25B
2029 Q2E $4.50B$1.81B$2.96B$7.89B$5.24B$301M $22.69B +1% $6.12B $1.14B $3.98B +19 $3.25B
2029 Q3E $4.95B$1.89B$3.42B$8.26B$5.25B$302M $24.06B +1% $6.49B $1.20B $4.24B +19 $3.40B
2029 Q4E $4.78B$1.90B$3.60B$8.10B$5.25B$302M $23.93B +1% $6.47B $1.20B $4.22B +19 $3.33B
2030 Q1E $4.39B$1.67B$3.24B$7.75B$5.26B$303M $22.60B +1% $6.10B $1.14B $3.97B +19 $3.08B
2030 Q2E $4.65B$1.83B$3.01B$7.98B$5.26B$304M $23.02B +1% $6.21B $1.16B $4.04B +19 $3.09B
2030 Q3E $5.12B$1.91B$3.47B$8.35B$5.27B$305M $24.42B +1% $6.59B $1.21B $4.30B +19 $3.23B
2030 Q4E $4.94B$1.92B$3.66B$8.19B$5.27B$305M $24.28B +1% $6.56B $1.21B $4.28B +19 $3.16B
2031 Q1E $4.53B$1.69B$3.29B$7.83B$5.28B$306M $22.93B +1% $6.19B $1.15B $4.03B +19 $2.92B
2031 Q2E $4.80B$1.85B$3.05B$8.07B$5.28B$307M $23.36B +1% $6.30B $1.17B $4.10B +19 $2.93B

Every row is projected. A year-over-year change is shown only where the quarter it compares against exists — an em dash means there is no comparable quarter, not a flat year.

Track record

Model revisions

Assumptions are marked to reality as each quarter prints. Every change is appended here, with the fair value the model produced at the time, so the model's own history stays visible.

DateFair value thenNote
2026-08-27 $133.02 First published model. Built on the fiscal 2026 fourth quarter reported 29 July 2026: six disclosed segment lines across twenty quarters, four-factor seasonality on the four segments where the derived shape beats its own window-to-window spread, and a base case pinned to trailing deseasonalised growth rather than to guidance.